Cholesterol Ester Transfer Protein Inhibitor Review. Issue 9 (October 2017)

• Record Type: Journal Article
• Authors: Hu, Jerry; Walker, Scot
• Is Part Of: Hospital pharmacy. Volume 52:Issue 9(2017)
• Page Start: 596
• Page End: 598
• Publication Date: 2017-10
• Subjects: investigational drugs -- drug information -- formulary management/P&T -- cardiovascular; Hospital pharmacies -- Periodicals; Pharmacy Service, Hospital; Hospital pharmacies; Periodicals; Periodicals; 615.1
• DOI: 10.1177/0018578717729669
• Languages: English
• ISSNs: 0018-5787

Abstract

Treatment of blood cholesterol is part of a strategy to lower atherosclerotic cardiovascular (ASCVD) risk. While use of HMG-CoA reductase inhibitors to modify cholesterol levels is the primary means of lowering the risk of an ASCVD event, residual risk remains. A new strategy being investigated is the use of cholesterol ester transfer protein (CETP) inhibitors to raise the levels of high-density lipoprotein cholesterol (HDL-C) and lower low-density lipoprotein cholesterol (LDL-C). While initial large-scale studies demonstrated no reduction of cardiovascular events, one CETP inhibitor, anacetrapib, has demonstrated a reduction in cardiovascular events in the REVEAL trial.